Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

NCT01717066 is registered in ClinicalTrials.gov with ShenFeng as lead sponsor.

NCT NCT01717066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01717066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Lead sponsor
ShenFeng
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2012
Completion date
May 31, 2015
Enrollment
480 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

stage i hepatocellular carcinoma, stage ii hepatocellular carcinoma